Diagnostic accuracy of glycogen phosphorylase BB for myocardial infarction: A systematic review and meta‐analysis

Purpose We tried to investigate the diagnostic accuracy of glycogen phosphorylase BB as a cardiac marker for myocardial infarction. Methods We searched through different electronic databases (PubMed, Google‐scholar, Embase, and Cochrane Library) to locate relevant articles. Studies, with sufficient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical laboratory analysis 2022-05, Vol.36 (5), p.e24368-n/a
Hauptverfasser: Ghimire, Anup, Giri, Subarna, Khanal, Niharika, Rayamajhi, Shivani, Thapa, Anjila, Bist, Anil, Devkota, Surya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose We tried to investigate the diagnostic accuracy of glycogen phosphorylase BB as a cardiac marker for myocardial infarction. Methods We searched through different electronic databases (PubMed, Google‐scholar, Embase, and Cochrane Library) to locate relevant articles. Studies, with sufficient data to reconstruct a 2 × 2 contingency table, met our inclusion criteria were included. Three reviewers independently screened the articles. Discrepancies were resolved by other reviewers. Unpublished data were requested from the authors of the study via email. Subsequently, data extraction was done using a standardized form and quality assessment of studies using the QUADAS‐2 tool. Meta‐analysis was done using a bivariate model using R software. Results Fourteen studies were selected for the final evaluation, which yielded the summary points: pooled sensitivity 87.77% (77.52%–93.72%, I2 = 86%), pooled specificity 88.45% (75.59%–94.99%, I2 = 88%), pooled DOR 49.37(14.53–167.72, I2 = 89%), and AUC of SROC was 0.923. The lambda value of the HSROC curve was 3.670. The Fagan plot showed that GPBB increases the pretest probability of myocardial infarction from 46% to 81% when positive, and it lowers the same probability to 12% when negative. Conclusion With these results, we can conclude that GPBB has modest accuracy in screening myocardial infarction, but the limitations of the study warrant further high‐quality studies to confirm its usefulness in predicting myocardial infarction (MI). Our study is a systematic review and meta‐analysis done to evaluate GPBB as a potential biomarker for the prompt diagnosis of MI. 14 studies were selected for evaluation after a thorough screening. Our results (AUC = 0.923, DOR = 49.37) have led to the conclusion that GPBB serves as a moderately accurate biomarker for the early diagnosis of MI and could revolutionize the treatment protocol currently set for MI. We do recognize that our paper comes with its set of limitation therefore, further studies on the topic is still needed.
ISSN:0887-8013
1098-2825
DOI:10.1002/jcla.24368